BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld
BioWorld
April 29, 2009
View Archived Issues
Ardea Licenses MEK Inhibitors to Bayer in Deal Valued at $407M
Ardea Biosciences Inc. licensed its MEK inhibitors to Bayer Healthcare AG to develop potential treatments for cancer, in a deal worth up to $407 million. (BioWorld Today)
Read More
Agencies in 'Pre-Pandemic' Mode as Flu Cases Grow
Read More
Dendreon: Provenge Drops Death Risk 22.5%, Ups Survival 4.1 Mos.
Read More
Cephalon Updating Treanda Label After Patient Dies from Skin Rash
Read More
UK Bio Bailout Welcome, but Less than Hoped for
Read More
Clinic Roundup
Read More
Other News To Note
Read More
Financings Roundup
Read More